1. Home
  2. CRSP vs ITGR Comparison

CRSP vs ITGR Comparison

Compare CRSP & ITGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRSP
  • ITGR
  • Stock Information
  • Founded
  • CRSP 2013
  • ITGR 1970
  • Country
  • CRSP Switzerland
  • ITGR United States
  • Employees
  • CRSP N/A
  • ITGR N/A
  • Industry
  • CRSP Biotechnology: Biological Products (No Diagnostic Substances)
  • ITGR Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • Sector
  • CRSP Health Care
  • ITGR Health Care
  • Exchange
  • CRSP Nasdaq
  • ITGR Nasdaq
  • Market Cap
  • CRSP 4.0B
  • ITGR 4.3B
  • IPO Year
  • CRSP 2016
  • ITGR 2000
  • Fundamental
  • Price
  • CRSP $47.25
  • ITGR $133.12
  • Analyst Decision
  • CRSP Buy
  • ITGR Strong Buy
  • Analyst Count
  • CRSP 19
  • ITGR 8
  • Target Price
  • CRSP $73.69
  • ITGR $140.14
  • AVG Volume (30 Days)
  • CRSP 1.8M
  • ITGR 299.7K
  • Earning Date
  • CRSP 11-05-2024
  • ITGR 10-24-2024
  • Dividend Yield
  • CRSP N/A
  • ITGR N/A
  • EPS Growth
  • CRSP N/A
  • ITGR 32.56
  • EPS
  • CRSP N/A
  • ITGR 3.25
  • Revenue
  • CRSP $202,829,000.00
  • ITGR $1,712,620,000.00
  • Revenue This Year
  • CRSP N/A
  • ITGR $9.98
  • Revenue Next Year
  • CRSP $526.27
  • ITGR $7.06
  • P/E Ratio
  • CRSP N/A
  • ITGR $40.02
  • Revenue Growth
  • CRSP 19.31
  • ITGR 12.41
  • 52 Week Low
  • CRSP $43.42
  • ITGR $84.75
  • 52 Week High
  • CRSP $91.10
  • ITGR $140.91
  • Technical
  • Relative Strength Index (RSI)
  • CRSP 44.94
  • ITGR 53.27
  • Support Level
  • CRSP $50.60
  • ITGR $124.16
  • Resistance Level
  • CRSP $59.07
  • ITGR $139.00
  • Average True Range (ATR)
  • CRSP 2.84
  • ITGR 3.37
  • MACD
  • CRSP -0.35
  • ITGR 0.45
  • Stochastic Oscillator
  • CRSP 7.48
  • ITGR 53.49

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for to treat Type 1 diabetes.

About ITGR Integer Holdings Corporation

Integer Holdings Corp is a manufacturer of medical device components used by original equipment manufacturers in the medical industry. The company also develops batteries used in nonmedical applications in the energy, military, and environmental markets. The firm organizes itself into two business segments based on the product type: medical and nonmedical. The medical segment uses the firm's technologies to produce components and finished medical devices, and it generates the vast majority of revenue. The company earns more than half of its revenue in the United States.

Share on Social Networks: